Illinois Municipal Retirement Fund Decreases Stock Position in Illumina, Inc. $ILMN

Illinois Municipal Retirement Fund cut its position in Illumina, Inc. (NASDAQ:ILMN) by 5.0% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 97,471 shares of the life sciences company’s stock after selling 5,148 shares during the period. Illinois Municipal Retirement Fund’s holdings in Illumina were worth $12,014,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in ILMN. Empowered Funds LLC grew its holdings in shares of Illumina by 113.7% during the first quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company’s stock worth $737,000 after buying an additional 4,940 shares in the last quarter. Sivia Capital Partners LLC purchased a new position in shares of Illumina in the second quarter worth about $621,000. CW Advisors LLC purchased a new position in shares of Illumina in the second quarter worth about $275,000. Marshall Wace LLP boosted its position in Illumina by 49.0% during the second quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company’s stock worth $5,691,000 after acquiring an additional 19,618 shares during the last quarter. Finally, Cresset Asset Management LLC grew its stake in Illumina by 30.9% during the 2nd quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company’s stock valued at $706,000 after acquiring an additional 1,748 shares in the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Keith A. Meister sold 235,000 shares of Illumina stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $163.63, for a total transaction of $38,453,050.00. Following the sale, the director owned 2,830,452 shares of the company’s stock, valued at approximately $463,146,860.76. The trade was a 7.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Scott D. Ericksen sold 500 shares of the company’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $160.00, for a total value of $80,000.00. Following the completion of the transaction, the chief accounting officer owned 14,446 shares in the company, valued at $2,311,360. This represents a 3.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,003,769 shares of company stock worth $155,710,908 over the last quarter. 2.90% of the stock is currently owned by corporate insiders.

Illumina Trading Up 1.7%

Shares of ILMN opened at $190.25 on Friday. Illumina, Inc. has a 12-month low of $88.00 and a 12-month high of $196.66. The firm has a market capitalization of $28.78 billion, a P/E ratio of 34.59, a P/E/G ratio of 3.50 and a beta of 1.47. The firm has a 50-day moving average price of $165.54 and a 200 day moving average price of $143.04. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. The company had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a net margin of 19.42% and a return on equity of 31.01%. Illumina’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Sell-side analysts forecast that Illumina, Inc. will post 5.21 EPS for the current year.

Analysts Set New Price Targets

ILMN has been the subject of a number of recent research reports. Piper Sandler increased their price objective on shares of Illumina from $170.00 to $200.00 and gave the company an “overweight” rating in a report on Wednesday, July 1st. Canaccord Genuity Group boosted their target price on Illumina from $140.00 to $190.00 and gave the stock a “hold” rating in a report on Tuesday. Barclays upped their price target on Illumina from $122.00 to $145.00 and gave the company an “underweight” rating in a research report on Wednesday, June 24th. JPMorgan Chase & Co. raised Illumina from a “neutral” rating to an “overweight” rating and increased their price target for the company from $125.00 to $185.00 in a report on Wednesday, June 10th. Finally, Wall Street Zen downgraded Illumina from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Eight research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Illumina presently has an average rating of “Hold” and an average price target of $153.56.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.